Sam Davis represents public and private life sciences companies, venture capital firms and their portfolio companies, and early stage companies focused on the life sciences sector, in matters involving biotechnology, medical devices, diagnostics and health care information technology.
Sam has extensive experience with startup and formation matters, venture capital financings, initial public offerings and capital market transactions, mergers & acquisitions and purchase option agreements, strategic collaborations, cross-border transactions particularly in China, and other complex matters.
Prior to joining McDermott, Sam spent several years at an international firm headquartered in Boston, as well as major international firms in Shanghai and Hong Kong.
Counseled a NASDAQ-listed molecular insights company in its $2.4 billion sale to a multinational health care company*
Counseled an Israeli multinational pharmaceutical company in its sale of its specialty global women’s health business to three buyers for a combined value of $2.5 billion*
Counseled a clinical-stage biopharmaceutical company on the closing of its initial public offering in which the gross proceeds from the IPO were approximately $86.3 million, before deducting underwriting discounts and commissions and estimated offering expenses*
Counseled a clinical-stage biopharmaceutical company on its shelf registration, follow-on and at-the-market (ATM) offerings*
Counseled a US-based manufacturer of proton therapy systems on a $150 million acquisition by a Chinese buyer*
Counseled a newly-formed cancer diagnostic company on its acquisition of a US-based company and subsequent $110 million Series A Financing transaction, subject to achievement of certain clinical milestones*
Counseled client on a merger of equals of clinical-stage cancer therapy companies and a subsequent $49 million Series A Financing transactions with an upfront payment of $80 million in connection with a collaboration agreement and global license*
Counseled a venture capital firm on its formation of a $250 million medical device incubator, with co-investment from global pharmaceutical companies*
Counseled a clinical-stage gene therapy company on its $60 million cross-over Series B round of financing*
Counseled a pre-clinical neuroscience company focused on neurodegenerative diseases on its $55 million Series A Financing transaction*
Counseled a pre-clinical company focused on age-related diseases on its $23 million Series A Financing*
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.